Zerbaxa ASPECT-NP Trial Demonstrated Noninferiority to Meropenem for Ventilated Nosocomial Pneumonia

ECCMID 2019: Results of the ASPECT-NP trial showed that an investigational dose of Merck's ceftolozane-tazobactam was noninferior to meropenem in treating adults with ventilated nosocomial pneumonia.